FAMILY ADAPTATION TO NEWBORN SCREENING FOR FRAGILE X SYNDROME

家庭对新生儿脆性 X 综合征筛查的适应

基本信息

  • 批准号:
    7482836
  • 负责人:
  • 金额:
    $ 26.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-01 至 2013-06-30
  • 项目状态:
    已结题

项目摘要

A. SPECIFIC AIMS Fragile X syndrome (FXS) is the most common inherited form of intellectual disability. However, because phenotypic features are not evident at birth, FXS must be discerned through abnormalities in development or behavior. Parents typically go through an extended "odyssey" before FXS is diagnosed (Bailey, Skinner, Hatton, & Roberts, 2000; Bailey, Skinner, & Sparkman, 2003). The average age of diagnosis is 32-36 months for full mutation males, and usually later for girls, since females are more mildly affected. As a result, children miss the opportunity to participate in early intervention and parents often have additional children with FXS without knowing reproductive risk. Newborn screening would provide parents the opportunity to learn about their child's FXS status and their own reproductive risk, in addition to other likely benefits (Bailey, 2004; Bailey, Skinner, & Warren, 2005; Bailey, Beskow, Davis, & Skinner, 2006). However, concerns have been raised, including lack of a treatment, consent issues, possible parent anxiety or disrupted parent-child relations, carrier disclosure, and limited state capacity to support families (Bailey et al., accepted pending minor revisions). Thus newborn screening for FXS is controversial. Parents report frustration with professionals and the health care system, consider advantages of screening more likely than disadvantages, and have a broad view of "benefit" and "treatment" (Bailey et al., 2006; Bailey, Skinner, & Sparkman, 2003; Skinner, Sparkman, & Bailey, 2003). These and other studies (e.g., Campbell & Ross, 2003; Davidson et al., 2000; Helton et al., 1991; Whitehead & Strange, 2006) show that parents strongly support voluntary expanded newborn screening. However, professionals generally insist on screening only for conditions with clear medical treatments that improve health outcomes (Botkin et al., 2006; Natowicz, 2005). Professional organizations oppose carrier testing for infants, arguing that screening should only be done if there is proven medical benefit to the infant (American Academy of Pediatrics, 2000; ASHG/ACMG, 1995). Fragile X syndrome is an excellent prototype for studying issues that will arise in an era of technical capacity for greatly expanded newborn screening. Project 3 focuses on family adaptation to newborn screening for FXS. The study will provide important information about the consequences of screening for both carriers and children with the full mutation FXS.
A.具体目标 脆性X综合征(FXS)是最常见的遗传性智力残疾。但由于 表型特征在出生时并不明显,FXS必须通过发育异常或 行为在FXS被诊断出来之前,父母通常会经历一段漫长的“奥德赛”(Bailey,Skinner, Hatton,& Roberts,2000; Bailey,Skinner,&斯帕克曼,2003).平均确诊年龄为32-36个月 对于完全突变的男性来说,通常对女孩来说更晚,因为女性受到的影响更轻微。因此,儿童 错过了参与早期干预的机会,父母经常有额外的FXS儿童 而不知道生殖风险。 新生儿筛查将为父母提供机会,了解他们孩子的FXS状态和他们自己的FXS状态。 生殖风险,除了其他可能的好处(贝利,2004年;贝利,斯金纳,沃伦,2005年;贝利, Beskow,Davis,& Skinner,2006).然而,人们提出了一些担忧,包括缺乏治疗,同意 问题,可能的父母焦虑或亲子关系中断,运营商披露,以及有限的国家能力 以支持家庭(Bailey等人,接受,等待小的修订)。因此,新生儿FXS筛查是 争议父母报告对专业人员和医疗保健系统感到沮丧,考虑 筛选的可能性大于缺点,并且对“益处”和“治疗”有广泛的看法(Bailey等人, Bailey,Skinner,&斯帕克曼,2003; Skinner,斯帕克曼,& Bailey,2003).这些和其他研究(例如, 坎贝尔和罗斯,2003年;戴维森等人,2000; Helton等人,1991; Whitehead & Strange,2006)表明 家长大力支持自愿扩大新生儿筛查。然而,专业人士普遍认为, 仅筛查具有明确药物治疗可改善健康结果的疾病(Botkin等人,二○ ○六年; Natowicz,2005)。专业组织反对对婴儿进行携带者检测,认为筛查应该 只有在证明对婴儿有医疗益处的情况下才能这样做(美国儿科学会,2000年; ASHG/ACMG,1995年)。 脆性X染色体综合征是研究技术能力时代将出现的问题的极好原型 用于大幅度扩大新生儿筛查。项目3侧重于家庭对新生儿FXS筛查的适应。 这项研究将提供关于筛查携带者和 FXS基因完全突变的孩子

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Donald B Bailey其他文献

Donald B Bailey的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Donald B Bailey', 18)}}的其他基金

Child and Family Consequences of Congenital Zika Syndrome in Brazil
巴西先天性寨卡综合症对儿童和家庭的影响
  • 批准号:
    9912805
  • 财政年份:
    2017
  • 资助金额:
    $ 26.77万
  • 项目类别:
Early Check: A Collaborative Innovation to Facilitate Pre-Symptomatic Clinical Trials in Newborns
早期检查:促进新生儿症状前临床试验的协作创新
  • 批准号:
    9975249
  • 财政年份:
    2016
  • 资助金额:
    $ 26.77万
  • 项目类别:
NORTH CAROLINA: PILOT TEST AND DEVELOPMENT OF NEWBORN SCREENING PROGRAM CAPACITY
北卡罗来纳州:新生儿筛查计划能力的试点测试和发展
  • 批准号:
    9134040
  • 财政年份:
    2015
  • 资助金额:
    $ 26.77万
  • 项目类别:
Decisional Capacity and Informed Consent in Fragile X Syndrome
脆性 X 综合征的决策能力和知情同意
  • 批准号:
    8554306
  • 财政年份:
    2012
  • 资助金额:
    $ 26.77万
  • 项目类别:
Decisional Capacity and Informed Consent in Fragile X Syndrome
脆性 X 综合征的决策能力和知情同意
  • 批准号:
    8699808
  • 财政年份:
    2012
  • 资助金额:
    $ 26.77万
  • 项目类别:
Decisional Capacity and Informed Consent in Fragile X Syndrome
脆性 X 综合征的决策能力和知情同意
  • 批准号:
    8437309
  • 财政年份:
    2012
  • 资助金额:
    $ 26.77万
  • 项目类别:
ADMINISTRATIVE CORE
行政核心
  • 批准号:
    7482837
  • 财政年份:
    2008
  • 资助金额:
    $ 26.77万
  • 项目类别:
ELSI Scale-Up: Large Sample Gene Discovery & Disclosure
ELSI 放大:大样本基因发现
  • 批准号:
    6831405
  • 财政年份:
    2004
  • 资助金额:
    $ 26.77万
  • 项目类别:
ELSI Scale-Up: Large Sample Gene Discovery & Disclosure
ELSI 放大:大样本基因发现
  • 批准号:
    7273900
  • 财政年份:
    2004
  • 资助金额:
    $ 26.77万
  • 项目类别:
ELSI Scale-Up: Large Sample Gene Discovery & Disclosure
ELSI 放大:大样本基因发现
  • 批准号:
    6944520
  • 财政年份:
    2004
  • 资助金额:
    $ 26.77万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 26.77万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 26.77万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 26.77万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 26.77万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 26.77万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 26.77万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 26.77万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 26.77万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 26.77万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 26.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了